Table 2.
Clinical characteristics of 86 TED patients.
| Parameter | TED patients (n = 86) |
|---|---|
| CAS | 1.64 ± 1.28 |
| Spontaneous orbital pain (n, %) | 6 (7.0) |
| Gaze-evoked orbital pain (n, %) | 5 (5.8) |
| Eyelid erythema (n, %) | 9 (10.5) |
| Eyelid edema (n, %) | 62 (72.1) |
| Conjunctival redness (n, %) | 30 (37.2) |
| Chemosis (n, %) | 11 (12.8) |
| Caruncle edema (n, %) | 16 (18.6) |
| CAS ≥ 3 points (n, %) | 20 (23.3) |
| Thyroid status | |
| Euthyroidism (n, %) | 57 (66.3) |
| Hyperthyroidism (n, %) | 18 (20.9) |
| Hypothyroidism (n, %) | 10 (11.6) |
| FT3 (pmol/L) | 5.18 ± 0.77 |
| FT4 (pmol/L) | 11.65 ± 2.24 |
| TSH (mIU/L) | 1.96 (1.03, 2.94) |
| TRAb (IU/ml) | 1.17 ± 0.34 |
| TGAb (IU/ml) | 0.21 (0.01, 3.73) |
| TPOAb (IU/ml) | 3.20 (0.64, 17.27) |
| TPOAb (+) (n, %) | 28 (32.6) |
| TGAb (+) (n, %) | 20 (23.3) |
| TPOAb (+) and TGAb (+) (n, %) | 14 (16.3) |
| TPOAb (+) and TGAb (-) (n, %) | 14 (16.3) |
| TPOAb (-) and TGAb (+) (n, %) | 6 (6.9) |
| TPOAb (-) and TGAb (-) (n, %) | 52 (60.5) |
| EUGOGO classification of severity of TED | |
| Mild (n, %) | 20 (23.3) |
| Moderate-to-severe (n, %) | 63 (73.3) |
| Sight-threatening (n, %) | 3 (3.5) |
| DON (n, %) | 3 (3.5) |
| Corneal ulcer (n, %) | 0 (0.0) |
| NOSPECS classification | 4.13 ± 1.24 |
| Bilateral (n, %) | 74 (86.0) |
| Eyelid retraction (n, %) | 52 (60.5) |
| Proptosis (n, %) | 72 (83.7) |
| Lagophthalmos (n, %) | 20 (23.3) |
| Visual acuity | 0.91 ± 0.24 |
| Exophthalmos (mm) | 19.22 ± 3.28 |
| Gorman diplopia score | 2 (0, 3) |
Values are presented as mean ± SD or median (25th percentile, 75th percentile), or number, percentage (n, %), according to distribution; Abbreviations: TED denotes thyroid eye disease; CAS clinical activity score; FT3 Free Triiodothyronine; FT4 Free Thyroxine; TSH Thyroid Stimulating Hormone; TRAb thyrotrophin receptor antibody; TGAb thyroid globulin antibodies; TPOAb thyroid peroxidase antibodies; DON dysthyroid optic neuropathy.